The FDA has determined that the MyGlucoHealth Wireless System is substantially equivalent to legally marketed predicate devices and can be marketed subject to general controls. The device is classified as a class II glucose test system. While the device is cleared for marketing, the manufacturer must still comply with requirements for registration, listing, labeling, good manufacturing practices, medical device reporting, and other applicable regulations.